LEP and metabolic dysfunction-associated steatohepatitis: Leptin replacement therapy has shown promising results in treating metabolic steatohepatitis (MASH) patients with leptin levels below the 25th percentile for their sex and BMI category (“relative leptin deficiency”, RLD).